Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Assets (2024 - 2025)

Prelude Therapeutics' Other Non-Current Assets history spans 2 years, with the latest figure at $110000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $110000.0; the TTM value through Dec 2025 reached $110000.0, changed 0.0%, while the annual FY2025 figure was $110000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $110000.0 at Prelude Therapeutics, roughly flat from $110000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.0 million in Q1 2024 and bottomed at $110000.0 in Q4 2024.